TNGX stock hits record high on inking collaboration deal with ERAS
The article reports that TNGX stock has reached a record high following the announcement of a new collaboration deal with ERAS. This partnership is likely perceived positively by investors, driving the significant increase in TNGX's stock value.
Why Is Erasca, Inc. (ERAS) Stock Down Today?
Erasca, Inc. (ERAS) stock is down 3.87% at $17.12, reflecting negative investor sentiment despite strong technical indicators with the stock trading above both its 50-day and 200-day moving averages. Analyst sentiment is bullish, and Meyka's AI assigns ERAS an overall moderate grade of B, with future forecast models projecting varied returns. The decline comes with a 30% lower trading volume than average, suggesting selling interest.
Erasca (ERAS) Among the Best Performing Stocks of Q1 2026 to Watch for Q2
Erasca, Inc. (NASDAQ: ERAS) is highlighted as one of the best-performing stocks in Q1 2026, with analysts increasing price targets due to promising clinical trials for its lead cancer drug, ERAS-0015, and an expanded licensing agreement in Asia. H.C. Wainwright raised its price target to $20, citing encouraging results from the pan-RAS asset, while Stifel also increased its target to $20, expecting $3.2 billion in global revenue by 2035 following the company's full access to Joyo Pharmatech's data. The article also includes promotional content for an "AI stock" that supposedly has 10,000% upside potential.
JPMorgan Chase & Co. Has $2.77 Million Stock Holdings in Erasca, Inc. $ERAS
JPMorgan Chase & Co. reduced its stake in Erasca, Inc. (NASDAQ:ERAS) by 7.5% in the third quarter, now holding 1,269,042 shares valued at $2.77 million. Insiders have also been selling shares, with Ebun Garner selling 80,000 shares for $1.312 million and overall insider sales reaching $2.28 million in the last quarter, resulting in insiders owning 14.4% of the company. Despite these sales, analysts maintain a "Moderate Buy" consensus rating with an average price target of $16.63, while the stock currently trades near $17.81.
5 Best Performing Stocks of Q1 2026 to Watch for Q2
Erasca, Inc. (NASDAQ: ERAS) was among the top-performing stocks in Q1 2026. Analysts from H.C. Wainwright and Stifel increased price targets on ERAS due to its clinical progress with lead pan-RAS asset ERAS-0015 and an expanded licensing agreement in China. The company is a clinical-stage oncology firm focusing on RAS/MAPK pathway-driven cancers.
Insider Selling: Erasca (NASDAQ:ERAS) Insider Sells 80,000 Shares of Stock
Erasca insider Ebun Garner sold 80,000 shares of the company's stock on April 1st for $1.312 million, significantly reducing her ownership by 76.14%. This follows another substantial sale in January. Erasca shares are currently trading near a 1-year high, and the company holds a "Moderate Buy" rating from analysts.
Erasca (ERAS) Chief Legal Officer exercises options, sells 80K shares under 10b5-1 plan
Erasca's Chief Legal Officer, Ebun Garner, exercised stock options for 80,000 shares at $1.70 per share and subsequently sold all 80,000 common shares at a weighted-average price of $16.40. These transactions, which occurred on April 1, 2026, were conducted under a pre-arranged Rule 10b5-1 trading plan adopted in June 2024. Following the sale, Garner directly holds 25,076 shares of Erasca common stock.
Erasca CLO Ebun Garner sells $1.3m in ERAS stock
Erasca's Chief Legal Officer, Ebun Garner, sold 80,000 shares of ERAS common stock for approximately $1.31 million on April 1, 2026, after exercising options. The transaction was part of a pre-arranged trading plan. The company recently reported a significant net loss in 2025 but has strengthened its drug rights and received positive analyst price target increases due to its expansion into China and promising clinical trial results with ERAS-0015.
Erasca (NASDAQ:ERAS) Trading 8.2% Higher - Here's What Happened
Erasca (NASDAQ:ERAS) stock surged 8.2% to $17.96 with significantly lower trading volume. Analysts maintain a "Moderate Buy" rating with a $16.63 consensus target, and some have recently raised price targets. The clinical-stage biotech has a negative P/E ratio and has seen insider selling, though it slightly beat recent EPS estimates.
Erasca reports proposed 80,000-share sale (NASDAQ: ERAS)
Erasca, Inc. has filed a Form 144, indicating a proposed sale of 80,000 shares of common stock associated with a stock option, set for April 1, 2026, with an aggregate value of $1,312,354.68. The filing also notes 310,799,547 shares outstanding and details a prior sale of 120,000 shares for $670,809.15 on January 7, 2026. This Form 144 is a regulatory notice of intent, not confirmation of the sale's completion.
Erasca Inc stock hits 52-week high at 16.41 USD
Erasca Inc. (ERAS) stock reached a new 52-week high of $16.41, reflecting a 1243% gain over the past year and a 632% increase in the last six months. Despite a reported net loss in Q4 2025, several firms like Stifel, H.C. Wainwright, and Clear Street have maintained or raised their price targets to $20, citing promising clinical progress and strategic expansions. InvestingPro data, however, suggests the stock might be overvalued despite its strong price momentum and "GREAT" financial health score.
ERAS Technical Analysis & Stock Price Forecast
This article provides a technical analysis and stock price forecast for Erasca Inc. (ERAS), concluding with a "Strong Buy" sentiment based on various technical indicators. The analysis details momentum indicators like RSI and MACD, support and resistance levels, and performance relative to moving averages, offering insights for potential investors.
Erasca (ERAS) price target increased by 42.72% to 14.99
This article reports that the price target for Erasca (ERAS) has been increased by 42.72% to $14.99. No further details are provided regarding the reasons for this price target adjustment.
Erasca (ERAS) price target increased by 42.72% to 14.99
This article states that Erasca (ERAS) has had its price target increased by 42.72%, reaching a new target of 14.99. No other details about the company, the reason for the increase, or the analyst responsible are provided in this extremely brief article.
Erasca (ERAS) price target increased by 42.72% to 14.99
This article reports that the price target for Erasca (ERAS) has been increased by 42.72%, reaching a new target of 14.99. The information appears to be a direct data point without additional context or analysis provided in the snippet.
Erasca’s Stock Surges Higher Amid Pipeline Optimism
Erasca Inc.'s stock surged by 7.57% following positive FDA designations and promising results from its RAS-0015 treatment development. Analysts like JPMorgan, Stifel, and Mizuho have raised price targets, anticipating significant gains and global revenue potential from upcoming trial results in the challenging RAS-mutant solid tumor market. Strategic partnerships, enhanced liquidity, and patent protections further bolster investor optimism despite the inherent risks involved in biotech ventures.
Certain Stock Options of Erasca, Inc. are subject to a Lock-Up Agreement Ending on 23-MAR-2026.
Certain stock options of Erasca, Inc. are under a lock-up agreement set to expire on March 23, 2026. This agreement restricts directors, executive officers, and other securityholders from selling or transferring their shares or convertible securities for 60 days following the prospectus supplement date, specifically from January 21, 2026, to March 23, 2026. The restriction is to prevent market volatility after an offering.
How Erasca’s Expanded ERAS-0015 License and Narrower 2025 Loss Will Impact Erasca (ERAS) Investors
Erasca, Inc. reported a narrower net loss of US$124.55 million for 2025 and expanded its global license for ERAS-0015, a potential pan-RAS molecular glue, to include worldwide development and commercialization rights. This expansion simplifies future partnering and commercialization for Erasca's key pipeline asset. The article suggests that while funding is supported by recent equity raises, investors need to believe in the RAS-focused pipeline without current revenue to justify their investment.
Erasca (ERAS) adds 13%; soars 310% YTD
Erasca (ERAS) stock surged by 13% today, bringing its year-to-date gains to an impressive 310%. This significant rally indicates strong investor confidence or positive company developments.
5 Stocks Dominating Today’s Market Action
Erasca Inc. (NASDAQ:ERAS) experienced a significant rally, with its stock price soaring by 310% year-to-date and a 13.04% jump on Thursday, driven by analyst optimism and upcoming clinical trial data for its treatment candidate, ERAS-0015. The company's ERAS-0015 showed early promising results in January during dose escalations for RAS-mutant solid tumors, with confirmed and unconfirmed partial responses observed. Investors are closely watching the initial data from these clinical trials in both the US and China.
Erasca (NASDAQ:ERAS) Shares Up 10.3% on Better-Than-Expected Earnings
Erasca (NASDAQ:ERAS) shares surged 10.3% after the company reported better-than-expected quarterly earnings, beating consensus estimates by $0.01 per share. Analyst sentiment remains positive with several firms raising their price targets, contributing to a "Moderate Buy" consensus rating. Despite some insider selling, institutional investors hold a significant stake in the biopharmaceutical company, which focuses on developing precision medicines for cancer.
ERAS Surges as JP Morgan Raises Price Target | ERAS Stock News
JP Morgan has raised its price target for Erasca Inc. (ERAS) from $24.00 to $25.00, maintaining an 'Overweight' rating, following several other analysts who also increased their price targets for the precision oncology company. These adjustments reflect a strong positive outlook for Erasca's stock performance. The company specializes in therapies for RAS/MAPK pathway-driven cancers, with an average target price from Wall Street analysts of $14.70, implying an 8.49% upside from its current price.
JPMorgan Chase & Co. Increases Erasca (NASDAQ:ERAS) Price Target to $25.00
JPMorgan Chase & Co. has increased its price target for Erasca (NASDAQ:ERAS) to $25.00 from $24.00, maintaining an "overweight" rating and suggesting an 85.67% upside. This follows similar price target boosts from other analysts, resulting in an average "Moderate Buy" rating for the stock. The article also notes recent insider selling and details institutional holdings and the company's latest earnings report, which beat analyst estimates.
Guggenheim more than doubles Erasca (ERAS) PT following clinical progress and updated pipeline models
Guggenheim drastically increased its price target for Erasca (ERAS) after the company reported significant clinical advancements and refined its pipeline models. This bullish revision from $6 to $15 reflects strong confidence in Erasca's future potential. Investors and the market are likely to view this positive analyst coverage favorably.
Erasca Form 144: Foundation Lists Proposed Common Sales | ERAS SEC Filing - Form 144
The Erasca Foundation has filed a Form 144 with the SEC, indicating proposed sales of common stock. The filing lists multiple entries, each for 8,333 shares, with transaction dates in late 2025 and early 2026, and references NASDAQ as the market. An attorney's insight clarifies that this is routine reporting of planned affiliate dispositions.
Erasca’s Stock Faces Pressure as CMO Offloads Shares
Erasca Inc. (ERAS) stock is experiencing downward pressure after its Chief Medical Officer sold 20,000 shares, signaling potential confidence issues among executives. The company faces significant financial challenges, evidenced by negative profitability ratios and a high price-to-sales ratio, despite strong liquidity. Analysts maintain a negative sentiment, and the stock's technical analysis indicates a bearish trend with potential for further declines if it breaches key support levels.
FTAI Aviation To Rally More Than 43%? Here Are 10 Top Analyst Forecasts For Friday
This article compiles ten recent analyst rating changes and price target adjustments for various companies, including Adobe Inc., ServiceTitan Inc., KinderCare Learning Companies Inc., Nio Inc., Esperion Therapeutics Inc., Flagstar Bank, Nerdwallet Inc., Erasca Inc., SentinelOne Inc., and FTAI Aviation Ltd. Analysts from firms like Piper Sandler, Needham, Baird, HSBC, Citizens, Keefe, Bruyette & Woods, Morgan Stanley, HC Wainwright & Co., and BTIG have updated their outlooks on these stocks, with some seeing significant potential upside, such as FTAI Aviation Ltd. with a target rally of over 43%.
Erasca’s CMO Stock Sale Raises Eyebrows Amid Market Uncertainty
Erasca Inc. (ERAS) is facing market skepticism, with its stock down 7.03% due to unfavorable profitability metrics and recent insider share sales. The company exhibits strong liquidity but struggles with generating returns on assets and significant net income losses. Despite ambitious R&D investments, the CMO's sale of 20,000 shares further raises concerns about near-term performance and contributes to the prevailing bearish sentiment.
Analysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (ORIC), MindWalk Holdings (HYFT) and Erasca (ERAS)
This article provides analyst insights on three healthcare companies: Oric Pharmaceuticals (ORIC), MindWalk Holdings (HYFT), and Erasca (ERAS). Analysts from H.C. Wainwright have issued bullish sentiments, reiterating "Buy" ratings and setting price targets for each company. The article details the price targets, analyst ratings, and success rates for the featured analysts.
Erasca’s Chief Medical Officer Divests Shares Amid Strategic Uncertainties
Erasca Inc.'s Chief Medical Officer, Shannon Morris, sold 20,000 common shares for approximately $300,760, leading to investor concerns and a -7.03% drop in the company's stock. The company faces significant financial challenges, including negative profitability ratios, high price-to-sales, and substantial operating losses, despite a strong current ratio. Analysts maintain a negative outlook due to insider selling, lack of revenue generation, and a prevailing downtrend in the stock price.
Stifel reiterates Buy rating on Erasca stock, $20 target
Stifel reiterated a Buy rating and $20.00 price target on Erasca Inc (NASDAQ:ERAS) after the company's Q4 2025 financial results. Erasca reported a net loss of $29.1 million for Q4 2025 and $124.6 million for the full year, with management guiding for ERAS-0015 Phase 1 monotherapy data in the first half of 2026. The company's pro forma cash position of approximately $434 million is expected to fund operations into the second half of 2028, extending its cash runway beyond major clinical catalysts.
Stifel reiterates Buy rating on Erasca stock, $20 target
Stifel reiterated a Buy rating and a $20 price target for Erasca Inc. (NASDAQ: ERAS) following its fourth-quarter results, with the stock delivering an 897% return over the past year. The company reported a net loss of $29.1 million for Q4 2025 and ended the year with $341.8 million in cash, expected to fund operations into H2 2028. Erasca also secured worldwide rights for its RAS-targeting drug ERAS-0015, which has led to positive analyst sentiment from H.C. Wainwright, Stifel, and Clear Street, all raising price targets to $20.
Erasca stock price target raised to $20 by H.C. Wainwright on trial data
H.C. Wainwright raised its price target for Erasca Inc. (NASDAQ: ERAS) to $20 from $15, reiterating a Buy rating, due to positive clinical progress with its lead pan-RAS asset ERAS-0015. The drug demonstrated confirmed partial responses in early trials, and monotherapy data from U.S. and China trials are expected in the first half of 2026. This positive outlook is further supported by the company's expansion of global rights for ERAS-0015 and strategic partnerships.
Erasca, Inc. 2025 Annual Report: Erasing Cancer with Modality-Agnostic RAS/MAPK Pathway Therapeutics and Innovative Precision Oncology Strategies
Erasca, Inc. has released its 2025 Annual Report, highlighting significant operating losses and the ongoing need for substantial additional capital to fund its development programs. The company, an "emerging growth company" listed on Nasdaq under "ERAS," emphasizes the high volatility of its share price and the inherent risks in drug development and commercialization. Investors are advised to monitor financing, clinical progress, and strategic collaborations, given the company's development stage and lack of approved products and revenue.
Erasca (NASDAQ: ERAS) narrows 2025 loss and funds runway into H2 2028
Erasca, Inc. reported a narrowed net loss for 2025 at $124.5 million, down from $161.7 million in 2024, due to reduced operating expenses. The company's cash runway has been extended into the second half of 2028 following an upsizing of a public offering in January 2026, which raised approximately $258.8 million. Erasca also highlighted encouraging early clinical activity for its drug candidates ERAS-0015 and ERAS-4001, along with new U.S. composition-of-matter patents for its RAS-targeting franchise.
Erasca Reports Fourth Quarter and Full Year 2025 Business Updates and Financial Results
Erasca, Inc. reported its fourth quarter and full year 2025 financial results and business updates, highlighting encouraging early clinical activity for its pan-RAS molecular glue ERAS-0015, including ongoing responses across multiple RAS-mutant tumors. The company successfully completed a $259 million financing in January 2026, strengthening its balance sheet with $434 million in pro forma cash, expected to fund operations into the second half of 2028. Erasca anticipates further Phase 1 monotherapy data for ERAS-0015 in the first half of 2026 and for ERAS-4001 in the second half of 2026, continuing to advance its RAS-targeting franchise for cancer patients.
Erasca Reports Fourth Quarter and Full Year 2025 Business Updates and Financial Results
Erasca, Inc. reported its fourth quarter and full year 2025 financial results and provided business updates, highlighting encouraging early clinical activity for ERAS-0015. The company successfully completed a $259 million financing in January 2026, strengthening its balance sheet and extending its operational funding into the second half of 2028. Key upcoming milestones include Phase 1 monotherapy data for ERAS-0015 expected in the first half of 2026 and for ERAS-4001 in the second half of 2026.
Erasca 10-K: Net loss $124.55M; cash and securities $341.8M
Erasca reported a net loss of $124.546 million for the year 2025, which is an improvement compared to the previous year, and holds $341.8 million in cash and securities. An equity offering in January 2026 raised an additional $242.7 million net proceeds, extending their financial runway into the second half of 2028. The company is strategically focusing its pipeline on RAS/MAPK franchise programs, including advancing pan-RAS and pan-KRAS candidates into Phase 1 clinical trials.
A Look At Erasca (ERAS) Valuation After Securing Global Rights To ERAS-0015
Erasca has secured worldwide rights to its ERAS-0015 compound, leading to increased investor interest and a significant rise in its share price. Despite this, the stock is currently trading above the average analyst price target, with a fair value assessment suggesting it is overvalued. The article highlights that Erasca's valuation is heavily focused on the potential of ERAS-0015 and anticipates future clinical trial data.
Erasca (ERAS) to Release Earnings on Thursday
Erasca (NASDAQ:ERAS) is slated to report its Q4 2025 earnings before the market opens on Thursday, March 19th, with analysts projecting a loss of ($0.11) per share. The stock shares opened at $15.50 and have seen significant insider selling from corporate executives. Erasca currently holds a "Moderate Buy" consensus rating from analysts, with a target price of $10.33.
Erasca secures worldwide rights to RAS-targeting drug ERAS-0015
Erasca Inc. (NASDAQ:ERAS) has expanded its license agreement with Joyo Pharmatech Co., Ltd. to secure worldwide rights for ERAS-0015, an oral pan-RAS molecular glue targeting RAS-mutant cancers. The company's stock is trading near its 52-week high, reflecting substantial growth, and ERAS-0015 is currently undergoing Phase 1 trials with promising early results. Analysts have also raised price targets for Erasca following recent financial and strategic developments.
Erasca Exercises Option to Secure Worldwide Rights for ERAS-0015 Pan-RAS Molecular Glue to Include China, Hong Kong, and Macau
Erasca has exercised its option to expand its license agreement with Joyo Pharmatech to include China, Hong Kong, and Macau, granting Erasca worldwide rights for its pan-RAS molecular glue ERAS-0015. This move allows a unified global development and commercialization strategy for ERAS-0015, which has shown promising early clinical data in patients with RAS-mutant solid tumors. Initial Phase 1 monotherapy data for ERAS-0015 is anticipated in the first half of 2026.
Global cancer drug rights: Erasca takes ERAS-0015 worldwide
Erasca has secured worldwide rights for its pan-RAS molecular glue ERAS-0015 by expanding its license with Joyo to include China, Hong Kong, and Macau. The company will make a one-time payment to Joyo and plans a unified global development strategy for ERAS-0015, which has shown promising early clinical activity across various tumor types. Initial Phase 1 monotherapy data for ERAS-0015 are anticipated in the first half of 2026.
uniQure, Syndax and Erasca Are Drawing Analyst Interest Ahead of Key Drug Catalysts
Wall Street analysts are showing increased interest in three clinical-stage biotech companies: uniQure, Syndax Pharmaceuticals, and Erasca, ahead of significant drug catalysts. uniQure saw multiple upgrades following the departure of a key FDA official, improving its regulatory outlook for its Huntington's disease treatment. Syndax's potential in Idiopathic Pulmonary Fibrosis (IPF) and strong commercial performance are being undervalued, while Erasca is on a "Positive Catalyst Watch list" for its RAS inhibitor readout, with analysts seeing multiple pathways to success.
[144] Erasca, Inc. SEC Filing
This article details an SEC Form 144 filing by Erasca, Inc. concerning a proposed sale of securities. The filing indicates a sale of 20,000 shares of common stock with an aggregate market value of $300,768.64, acquired via stock options. The document includes filer and issuer information, securities details, and a statement regarding the absence of material adverse information not publicly disclosed.
Erasca (ERAS) CMO exercises options, sells 20,000 shares under 10b5-1 plan
Erasca, Inc.'s Chief Medical Officer, Morris Shannon, exercised options for 20,000 shares at $1.70 each and simultaneously sold 20,000 shares at a weighted-average price of $15.038 under a pre-arranged 10b5-1 trading plan. These transactions took place on March 4, 2026. Following these actions, Shannon still holds 515,800 stock options, which vest monthly over 48 installments starting February 1, 2024, contingent on continued service.
ERAS - Erasca, Inc. (ERAS): The RAS Specialist – Scaling the Precision Oncology Peak
This article analyzes Erasca, Inc. (ERAS), dubbing it "The RAS Specialist" in precision oncology. The author, Vestra, provides a valuation of US$11.56, indicating the stock is 26.3% overvalued based on intrinsic discount calculations. The analysis projects significant future revenue growth for Erasca.
TNGX Stock Hits Record High on Inking Collaboration Deal With ERAS
Tango Therapeutics (TNGX) shares surged to a record high after Erasca (ERAS) announced a collaboration to evaluate a combination therapy for MTAP-deleted RAS-mutant cancers. The agreement will combine Erasca’s ERAS-0015 with Tango's vopimetostat in a phase I/II study, aiming to provide a novel therapeutic strategy for these difficult-to-treat cancers. Tango Therapeutics also continues to advance its other pipeline candidates, including vopimetostat monotherapy and TNG456, and has ongoing collaborations with Revolution Medicines and Merck.
Clear Street raises Erasca stock price target on combination trial deal
Clear Street has increased its price target for Erasca Inc (NASDAQ:ERAS) from $11.00 to $20.00, maintaining a Buy rating, due to the company's clinical trial agreement with Tango Therapeutics. This deal focuses on evaluating ERAS-0015 in combination with vopimetostat for MTAP-deficient RAS-mutant cancers. The analyst also cited an increased probability of success for ERAS-0015 in pancreatic and non-small cell lung cancer, reflecting growing external validation of the drug candidate.
TNGX Stock Hits Record High on Inking Collaboration Deal With ERAS
Shares of Tango Therapeutics (TNGX) surged to a record high after announcing a clinical trial collaboration with Erasca (ERAS). The partnership will evaluate a combination therapy for MTAP-deleted RAS-mutant cancers, with Erasca providing ERAS-0015 and Tango Therapeutics sponsoring the study. This collaboration aims to enhance tumor growth suppression and improve treatment outcomes for patients with these difficult-to-treat cancers.
